MIAMI BEACH, Fla., Oct. 6, 2011 /PRNewswire/ -- Image-guided stereotactic radiosurgery (SRS) can be an effective and feasible approach for treating up to three spinal metastases, according to an international team of researchers reporting on the results of a recently concluded multi-institutional phase II trial. Samuel Ryu, M.D., head of neuro- and spinal oncology at the Henry Ford Health System in Detroit, who served as principal investigator for the trial, reported the results yesterday at the 2011 Annual Meeting of the American Society for Radiation Oncology (ASTRO) in Miami Beach, Florida.
The goals of the phase II trial (RTOG 0631) were to study the emerging technique of spine radiosurgery within the cooperative group setting, and to demonstrate the technical feasibility of treating spinal metastases with image-guided stereotactic radiosurgery.
"The message we get from the results of the phase II trial is that spine radiosurgery—despite its complexity—can be carried out successfully in the community hospital setting," said Dr. Ryu.
The study enrolled 46 patients treated at sixteen institutions between August 2009 and March 2011. Each patient received a single SRS treatment of 16 Gray units (a measure of radiation dose) after their treatment plans were rapid-reviewed by the principle investigator to ensure that they met previously-agreed-upon standards for quality of tumor coverage and compliance with normal tissue dose constraints and delivery of image-guided radiosurgery treatment.
Rapid review results showed that the treatment plans were optimal and acceptable in 100% of the patients. Spinal cord dose constraints were optimal for all patients (i.e. less than 10% of the spinal cord received 10 Gy of dose). Image-guidance treatment information showed optimal (91%) or acceptable (9%) compliance with pre-set parameters calling for less than 2-3 millimeters of difference between the target position at the time of treatment planning and the target position at the end of treatment.
According to the study protocol, previous clinical experience with stereotactic radiosurgery for spinal metastasis has shown it to be effective for pain control and improvement of neurological function in patients with epidural compression (Ryu 2003; Gertzen 2005; Degen 2005; Ryu 2004).
"As the technology for stereotactic radiosurgery becomes more widely available, we felt it was critical to study the emerging technique of spine radiosurgery in a phase II trial within a national cooperative group," Dr. Ryu said. "On the basis of the phase II results we are proceeding with a planned RTOG 0631 phase III study, comparing the effectiveness of SRS with conventional external beam radiotherapy, in terms of pain relief and quality of life outcomes in 240 patients with spine metastasis."
Degen JW, Gagnon GJ, Voyadzis JM, et al. CyberKnife stereotactic radiosurgical treatment of spinal tumors for pain control and quality of life. J Neurosurg Spine. 2: 540-5499, 2005.
Gerszten PC, Burton SA, Welch WC, Brufsky AM, Lembersky BC, Ozhasoglu C, Vogel WJ. Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer. 104: 2244–2254, 2005.
Ryu S, Yin FF, Rock J, et al. Image-guided and intensity-modulated radiosurgery for spinal metastasis. Cancer. 97: 2013-2018, 2003.
Ryu S, Rock J, Rosenblum M, Kim JH. Pattern of failure after single dose radiosurgery for single spinal metastasis. J Neurosurg. 101: 402-405, 2004.
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.
FOR INFORMATION CONTACT:
SOURCE Varian Medical Systems